- Action Plan for the Prevention, Care and Treatment of Viral Hepatitis
Building on the success of the nation’s first comprehensive cross-agency action plan, HHS released a 3-year update of the plan in April 2014. The updated plan builds on the foundation of the original action plan and seeks to harness:
- New recommendations for health care providers regarding screening for hepatitis C;
- Promising new developments in treatments for hepatitis C;
- Mounting public awareness of and concern about hepatitis B and hepatitis C; and
- The expansion of access to viral hepatitis prevention, diagnosis, care, and treatment offered by the Affordable Care Act.
READ ABOUT AND DOWNLOAD THE 100 PAGE PLAN
- New hepatitis C treatment very effective: Over 90 percent success rate in patients with cirrhosis
READ NEWS - Hepatitis C Treatment Viable in Primary Care
READ NEWS - Shorter Treatment Strategy Beats Hepatitis C
READ NEWS - Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination
Tablet for Genotype 1 Hepatitis C
READ NEWS - Future Data Anticipated from Abbvie's Clinical Trials Examines 3d Regimen with and Without Ribavirin, as Well as Treatment of Hepatitis C in Patients with Cirrhosis
READ NEWS - FDA OKs Major New Hepatitis C Drug, Sovaldi (Sofosbuvir)
READ NEWS - OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
READ NEWS - Hepatitis C Virus Maintains Infectivity for Weeks after Drying on Inanimate Surfaces at Room Temperature: Implications for Risks of Transmission
READ NEWS - AASLD 2013: Long term survival of liver fibrosis after virological cure (SVR) in patients with chronic hepatitis C (CHC): The avenue of the scars?
READ NEWS - Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naïve and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
READ NEWS - AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks
READ NEWS - AASLD 2013: Expanded Hepatitis C Screening Needed for Veterans, Baby Boomers, Pregnant Women
READ NEWS - AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%
READ NEWS - AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669
READ NEWS - Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected with HIV
READ NEWS - FDA Advisory Committee Supports Approval of Gilead’s Sofosbuvir for Chronic Hepatitis C Infection
READ NEWS - Making Recovery Month Matter
Service Improvement Blog brought to you by ATTC & NIATX
VIEW BLOG
Attention people living with Hepatitis C!!
You are invited to participate in a web-based interview. Please contact Mr. Leonard at pfcresearch@verizon.net. Qualified participants will complete three or four brief surveys which describe your day-to-day challenges with HCV. For each survey, you will receive $30.
As the new drugs are used to treat HCV, there will be new challenges to communications between patients and their health care providers. You can help. Please take this anonymous survey that will provide information to help health care professionals address their patients' concerns and ultimately lead to improved patient care.
To view the survey, please click on this link: http://www.sceptercme.com/hepcsurvey
- During 2014, Hepatitis C Association will continue to provide patients in substance abuse treatment centers with instructor led presentations about hepatitis C throughout the United States. For information, please call 908.769.8479. With specific sponsorship from Boehringer Ingelheim Pharmaceuticals, ten presentations are already scheduled in the State of Maryland.
- The International Liver Conference (EASL)
London, United Kingdom
April 9 – 13 - Digestive Diseases Week (DDW)
Chicago, IL
May 4 – 6 - The Liver Meeting (AASLD)
Boston, MA
November 7 – 11 - American Public Health Association Meeting & Exposition (APHA)
New Orleans, LA
November 15 – 19
This site complies with the HONcode standard for trustworthy health information:
verify here.
The information provided on this site is intended to support, not replace, the relationship that exists between a patient and his/her physician. Hepatitis C Association does not display commercial content or receive funding from advertising products or services.
Support line: 877-HELP-4-HEP (877-435-7443)
In My Own Words... Essay Contest!
The ATTC Network Coordinating Office, in partnership with Faces & Voices of Recovery Harm Reduction Coalition, Hepatitis C Association and Help4Hep invite you to share YOUR STORY OF RECOVERY from a substance use and/or mental health disorder while coping with Hepatitis C.
> Learn More
Vertex Patient Assistance for Incivek
855-837-8394 | www.incivek.com
Genentech Patient Assistance for
Pegasys & Copegus | 888-941-3331
Merck Patient Assistance for Victrelis
Peglntron & Rebetol
866-939-4372
Johnson & Johnson Patient
Assistance Foundation
800-652-6227 | www.jjpaf.org
Olysio Support (Medicare Excluded)
855-5-OLYSIO | www.olysio.com
Patient Access Network (PAN) Foundation for underinsured patients 866-316-PANF | www.panfoundation.org
Gilead Patient Assistance for Sovaldi
855-769-7284 | www.mysupportpath.com
